Shorter radiation course after surgery for thymoma and thymic carcinoma
Tests shorter radiation treatment after surgery in adults with thymic epithelial tumors.
Key facts
- Who runs it
- National Taiwan University Hospital
- Where
- Taiwan3 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Hypofractionated Adjuvant Radiotherapy for Thymic Epithelial Tumors
- Status
- Not yet recruiting
- People taking part
- 69 people, planned
- Started
- 1 Aug 2026
- Expected to end
- 30 Apr 2035
- Type of study
- Interventional
- Treatments tested
- Hypofractionated Adjuvant Proton Therapy
- Hypofractionated Adjuvant Photon Radiation Therapy
- Record updated
- 16 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a thymic epithelial tumor (thymoma or thymic carcinoma) who had surgery to remove the thymus and tumor. They will get a shorter course of radiotherapy after surgery, with photon or proton therapy.
- Age
- 18 years and older.
- Sex
- All sexes can join.
- Disease stage
- Masaoka-Koga stage I to III, confirmed by pathology, with a reason to give radiotherapy after surgery. Karnofsky performance status of 70% or more. Life expectancy of 1 year or more.
- Earlier treatment
- Must have had radical thymothymectomy. Earlier induction or neoadjuvant chemotherapy is allowed. No prior radiotherapy to the chest.
- Biomarker or test result
- Blood tests within 90 days before registration: white blood cell count >= 2000/mm3, platelet count >= 50,000/mm3, hemoglobin >= 8 g/dL, serum creatinine <= 2.0 mg/dL (177 µmol/L) or eGFR >= 30 mL/min, AST/ALT <= 2.5 times the upper limit of normal. Women who can become pregnant need a negative pregnancy test within 14 days before entry.
Main reasons for not taking part
- Prior radiotherapy to the chest.
- Planned chemotherapy at the same time as radiotherapy, or another experimental treatment during radiotherapy.
- Serious active illness, such as infection needing intravenous antibiotics, heart attack or heart failure needing hospital care in the last 6 months.
- Pregnant or breastfeeding women.
- Not willing to use contraception during radiotherapy and for 3 weeks after.
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Thymic epithelial tumor, including thymoma or thymic carcinoma, confirmed by pathology
- Received radical thymothymectomy
- Masaoka-Koga stage I to III disease with an indication for postoperative radiotherapy
- Age >= 18 years
- Karnofsky performance status >= 70%
- Life expectancy >= 1 year
- Sufficient bone marrow reserve, renal function, and liver function within 90 days prior to registration, defined as: white blood cell count >= 2000/mm3; platelet count >= 50,000/mm3; hemoglobin >= 8 g/dL; serum creatinine <= 2.0 mg/dL or estimated glomerular filtration rate >= 30 mL/min; AST/ALT <= 2.5 times the upper limit of normal
- Women of childbearing potential must have a negative qualitative serum or urine pregnancy test within 14 days prior to study entry
- Able to comply with study procedures and follow-up schedules and willing to provide study-specific informed consent
Who cannot take part
- Prior radiotherapy to the thorax
- Severe active comorbidities that, in the judgment of the investigator, make the patient inappropriate for study entry, interfere with safety or adverse event assessment, or limit compliance with study requirements, including: uncontrolled active infection requiring intravenous antibiotics at registration; transmural myocardial infarction <= 6 months prior to registration; unstable angina or congestive heart failure requiring hospitalization <= 6 months prior to registration; life-threatening uncontrolled clinically significant cardiac arrhythmias; hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at registration; uncontrolled psychiatric disorder
- Planned receipt of another investigational treatment during radiotherapy
- Planned concurrent chemotherapy during radiotherapy. Prior induction or neoadjuvant chemotherapy, or planned sequential adjuvant chemotherapy after adjuvant radiotherapy, is allowed
- Women of childbearing potential and sexually active male participants who are unwilling or unable to use medically acceptable contraception during radiotherapy and for 3 weeks after completing treatment
- Pregnant or breastfeeding women
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a multi-center, open-label, single-arm, prospective interventional study evaluating hypofractionated adjuvant radiotherapy (HART) after radical thymothymectomy in patients with thymic epithelial tumors. The study estimates 5-year local control and prospectively characterizes acute and late treatment-related adverse events, quality of life, cardiopulmonary function, and patterns of failure. Photon therapy and proton therapy are both protocol-acceptable modalities and are selected by shared decision-making rather than randomization.
The group in the trial
- Hypofractionated Adjuvant Radiation TherapyTreatment being tested
Participants receive hypofractionated adjuvant radiotherapy after radical thymothymectomy. Photon therapy or proton therapy is selected by shared decision-making between the participant and treating radiation oncologist.
Treatment: Hypofractionated Adjuvant Proton Therapy and Hypofractionated Adjuvant Photon Radiation Therapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Thymic Epithelial Tumor Hypofractionated Adjuvant Radiotherapy (THOR): A Multi-center Single-Arm Prospective Clinical Trial
- Plain-language title
- Shorter radiation course after surgery for thymoma and thymic carcinomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 16 July 2026